StockNews.AI
OSCR
StockNews.AI
167 days

Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

1. Ataraxis AI secured $20.4 million funding led by AIX Ventures. 2. Mario Schlosser, former CEO of OSCR, supported the financing.

2m saved
Insight
Article

FAQ

Why Bullish?

Mario Schlosser's involvement suggests confidence in innovative healthcare investments, potentially benefiting OSCR's stock as it aligns with growth trends in precision medicine.

How important is it?

The involvement of influential healthcare figures like Schlosser in funding related to a field crucial for OSCR marks significant industry relevance and growth potential.

Why Long Term?

Investments in AI precision medicine may position OSCR favorably in the evolving healthcare landscape over time.

Related Companies

AIXTHBQFNDGVOBV
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus,.

Related News